ConductScience.org, home

Trial · NCT04103450

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Number of Participants With Any Serious Adverse Event, and Treatment Emergent Adverse Event (>5%)52-Week Vibegron GroupAny SAE2Participants
Number of Participants With Any Serious Adverse Event, and Treatment Emergent Adverse Event (>5%)28-Week Vibegron GroupAny SAE3Participants
Number of Participants With Any Serious Adverse Event, and Treatment Emergent Adverse Event (>5%)52-Week Vibegron GroupAny non-SAE17Participants
Number of Participants With Any Serious Adverse Event, and Treatment Emergent Adverse Event (>5%)28-Week Vibegron GroupAny non-SAE3Participants
Number of Participants With Clinically Significant Changes in Hematology Parameters52-Week Vibegron Group0Participants
Number of Participants With Clinically Significant Changes in Hematology Parameters28-Week Vibegron Group0Participants
Number of Participants With Clinically Significant Changes in Chemistry Parameters52-Week Vibegron Group0Participants
Number of Participants With Clinically Significant Changes in Chemistry Parameters28-Week Vibegron Group0Participants
Number of Participants With Clinically Significant Changes in Urinary Parameters52-Week Vibegron Group0Participants
Number of Participants With Clinically Significant Changes in Urinary Parameters28-Week Vibegron Group0Participants
Number of Participants With Clinically Significant Changes in Coagulation Parameter52-Week Vibegron Group0Participants
Number of Participants With Clinically Significant Changes in Coagulation Parameter28-Week Vibegron Group0Participants
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)52-Week Vibegron GroupSBP-1.2Standard Deviation 12.50Millimeters of mercury
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)28-Week Vibegron GroupSBP0.1Standard Deviation 9.31Millimeters of mercury
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)52-Week Vibegron GroupDBP0.2Standard Deviation 8.79Millimeters of mercury
Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)28-Week Vibegron GroupDBP1.1Standard Deviation 6.82Millimeters of mercury
Change From Baseline in Heart Rate52-Week Vibegron Group3.3Standard Deviation 9.24Beats per minute
Change From Baseline in Heart Rate28-Week Vibegron Group-0.7Standard Deviation 7.98Beats per minute
Change From Baseline at Week 52 in the Average Number of Micturition Episodes Per Day52-Week Vibegron Group-2.43Standard Error 0.299Micturition Episodes per Day
Change From Baseline at Week 52 in the Average Number of Urgency Episodes Per Day52-Week Vibegron Group-2.90Standard Error 0.422Urgency Episodes per Day

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04103450/results